Skip to main content
Premium Trial:

Request an Annual Quote

Microchip Biotechnologies Reels in $18.1M in Financing

NEW YORK (GenomeWeb News) – Microchip Biotechnologies, which has developed a sample prep system for Sanger and next-generation sequencing, has received $18.1 million in series B financing from previous and new investors.

New investors include Domain Associates, Samsung Ventures, Western Technology Investment, and undisclosed individual investors; and previous investors Rona Syndicates and In-Q-Tel.

MBI, based in Pleasanton, Calif., is producing sample-processing systems based on its Apollo fluidics platform, which is designed for use in DNA and RNA sequencing, DNA-based forensics, and human identity testing.

The firm’s first offering is the Apollo 100 System, which it said can reduce the time, investment, and expense involved in sample preparation for Sanger cycle sequencing.

The financing will go toward marketing the Apollo 100 and developing the Apollo platform for next-generation sequencing applications.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.